Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Venous Thromboembolism | 33 | 2024 | 1882 | 3.760 |
Why?
|
Pulmonary Embolism | 39 | 2024 | 2598 | 3.510 |
Why?
|
Anticoagulants | 36 | 2023 | 4862 | 1.780 |
Why?
|
Venous Thrombosis | 12 | 2024 | 1327 | 1.630 |
Why?
|
Warfarin | 6 | 2023 | 1494 | 1.240 |
Why?
|
Blood Coagulation | 8 | 2020 | 1166 | 1.240 |
Why?
|
Thrombosis | 8 | 2023 | 2949 | 1.190 |
Why?
|
Heparin | 10 | 2022 | 1630 | 1.150 |
Why?
|
Patient Care Team | 9 | 2020 | 2517 | 1.100 |
Why?
|
Hemorrhage | 22 | 2023 | 3461 | 1.000 |
Why?
|
Thrombolytic Therapy | 10 | 2024 | 2059 | 0.750 |
Why?
|
Thrombophilia | 2 | 2021 | 308 | 0.740 |
Why?
|
Administration, Oral | 12 | 2023 | 4015 | 0.720 |
Why?
|
African Swine Fever | 1 | 2020 | 7 | 0.690 |
Why?
|
Blood Coagulation Factors | 4 | 2020 | 371 | 0.660 |
Why?
|
Fibrin Fibrinogen Degradation Products | 5 | 2021 | 428 | 0.630 |
Why?
|
Heparin, Low-Molecular-Weight | 5 | 2023 | 345 | 0.610 |
Why?
|
Antithrombins | 1 | 2021 | 295 | 0.590 |
Why?
|
Aftercare | 2 | 2020 | 911 | 0.540 |
Why?
|
Neoplasms | 19 | 2024 | 22340 | 0.490 |
Why?
|
Pyridones | 2 | 2020 | 816 | 0.490 |
Why?
|
Standard of Care | 1 | 2018 | 567 | 0.450 |
Why?
|
Blood Coagulation Disorders | 3 | 2021 | 349 | 0.430 |
Why?
|
Flank Pain | 1 | 2013 | 44 | 0.420 |
Why?
|
Renal Veins | 1 | 2013 | 103 | 0.420 |
Why?
|
Pyrazoles | 3 | 2020 | 2033 | 0.400 |
Why?
|
Extracorporeal Membrane Oxygenation | 2 | 2020 | 1480 | 0.380 |
Why?
|
Obesity, Morbid | 1 | 2023 | 1292 | 0.380 |
Why?
|
Emergency Service, Hospital | 7 | 2024 | 7875 | 0.350 |
Why?
|
Partial Thromboplastin Time | 2 | 2021 | 202 | 0.330 |
Why?
|
Patient Compliance | 1 | 2020 | 2692 | 0.320 |
Why?
|
Hospitalization | 6 | 2024 | 10808 | 0.320 |
Why?
|
Humans | 105 | 2024 | 765968 | 0.320 |
Why?
|
Anxiety | 1 | 2024 | 4671 | 0.320 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3100 | 0.300 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 3223 | 0.300 |
Why?
|
Practice Guidelines as Topic | 7 | 2021 | 7425 | 0.300 |
Why?
|
Peptide Fragments | 1 | 2020 | 5125 | 0.290 |
Why?
|
Thromboembolism | 3 | 2021 | 1003 | 0.280 |
Why?
|
Consensus | 5 | 2024 | 3202 | 0.280 |
Why?
|
Catheterization | 2 | 2020 | 1425 | 0.280 |
Why?
|
Factor VIIa | 1 | 2008 | 102 | 0.280 |
Why?
|
Hospital Rapid Response Team | 2 | 2018 | 56 | 0.270 |
Why?
|
Retrospective Studies | 22 | 2024 | 81514 | 0.260 |
Why?
|
Clinical Protocols | 4 | 2020 | 1441 | 0.250 |
Why?
|
Myeloproliferative Disorders | 2 | 2022 | 616 | 0.250 |
Why?
|
Middle Aged | 44 | 2024 | 223009 | 0.250 |
Why?
|
Risk Factors | 27 | 2024 | 74840 | 0.250 |
Why?
|
Critical Illness | 5 | 2021 | 2744 | 0.250 |
Why?
|
Stress, Physiological | 1 | 2012 | 1402 | 0.240 |
Why?
|
Pulmonary Artery | 3 | 2021 | 1935 | 0.240 |
Why?
|
Delivery of Health Care | 4 | 2024 | 5370 | 0.240 |
Why?
|
Female | 58 | 2024 | 396112 | 0.230 |
Why?
|
Depression | 1 | 2024 | 8237 | 0.230 |
Why?
|
Aged | 36 | 2024 | 171117 | 0.230 |
Why?
|
C-Reactive Protein | 4 | 2024 | 3850 | 0.220 |
Why?
|
Hematopoietic Cell Growth Factors | 2 | 2022 | 98 | 0.220 |
Why?
|
Male | 49 | 2024 | 363698 | 0.210 |
Why?
|
Acute Disease | 9 | 2024 | 7232 | 0.190 |
Why?
|
Risk Assessment | 13 | 2024 | 24282 | 0.180 |
Why?
|
Micropore Filters | 1 | 2020 | 23 | 0.180 |
Why?
|
Platelet Count | 2 | 2020 | 782 | 0.180 |
Why?
|
Ceruloplasmin | 1 | 2020 | 57 | 0.180 |
Why?
|
Iron Metabolism Disorders | 1 | 2020 | 24 | 0.180 |
Why?
|
Thrombocytopenia | 4 | 2020 | 1171 | 0.180 |
Why?
|
Hypereosinophilic Syndrome | 1 | 2021 | 97 | 0.180 |
Why?
|
Evidence-Based Medicine | 2 | 2010 | 3685 | 0.180 |
Why?
|
Pipecolic Acids | 1 | 2021 | 78 | 0.170 |
Why?
|
Drug Antagonism | 1 | 2019 | 50 | 0.170 |
Why?
|
Prothrombin | 1 | 2020 | 193 | 0.170 |
Why?
|
Endothelial Cells | 1 | 2012 | 3584 | 0.170 |
Why?
|
Adult | 30 | 2024 | 223044 | 0.170 |
Why?
|
Hirudins | 1 | 2021 | 179 | 0.170 |
Why?
|
Biomarkers, Pharmacological | 1 | 2020 | 162 | 0.160 |
Why?
|
von Willebrand Disease, Type 1 | 1 | 2019 | 5 | 0.160 |
Why?
|
Fibrinolytic Agents | 4 | 2023 | 2080 | 0.160 |
Why?
|
Probability | 1 | 2024 | 2475 | 0.160 |
Why?
|
Deamino Arginine Vasopressin | 1 | 2019 | 87 | 0.160 |
Why?
|
Biological Specimen Banks | 1 | 2024 | 786 | 0.150 |
Why?
|
Recombinant Proteins | 3 | 2021 | 6493 | 0.150 |
Why?
|
Ultrasonography, Doppler | 1 | 2020 | 460 | 0.150 |
Why?
|
Outpatients | 4 | 2018 | 1595 | 0.150 |
Why?
|
Drug Monitoring | 2 | 2021 | 962 | 0.150 |
Why?
|
Ambulatory Care | 2 | 2020 | 2778 | 0.140 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 248 | 0.140 |
Why?
|
Pyrrolidinones | 1 | 2018 | 116 | 0.140 |
Why?
|
Risk Adjustment | 1 | 2021 | 596 | 0.140 |
Why?
|
Thrombectomy | 3 | 2017 | 681 | 0.140 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 11868 | 0.140 |
Why?
|
Hemoglobinuria, Paroxysmal | 1 | 2017 | 86 | 0.140 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2021 | 12240 | 0.140 |
Why?
|
Hospitals, University | 1 | 2019 | 574 | 0.130 |
Why?
|
Emergency Treatment | 2 | 2018 | 494 | 0.130 |
Why?
|
Antiphospholipid Syndrome | 1 | 2018 | 166 | 0.130 |
Why?
|
Dextrocardia | 1 | 2016 | 37 | 0.130 |
Why?
|
Treatment Outcome | 14 | 2024 | 65188 | 0.130 |
Why?
|
Anemia | 3 | 2022 | 1511 | 0.130 |
Why?
|
Multiple Myeloma | 2 | 2023 | 5197 | 0.130 |
Why?
|
Amygdala | 1 | 2024 | 1377 | 0.130 |
Why?
|
Plasma | 1 | 2019 | 579 | 0.130 |
Why?
|
Heart Rate | 2 | 2024 | 4204 | 0.130 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 1 | 2020 | 245 | 0.120 |
Why?
|
Tissue Plasminogen Activator | 1 | 2021 | 1167 | 0.120 |
Why?
|
Decision Support Systems, Clinical | 1 | 2024 | 1175 | 0.120 |
Why?
|
History, 19th Century | 1 | 2017 | 711 | 0.120 |
Why?
|
Leukemia | 1 | 2022 | 1522 | 0.110 |
Why?
|
Patient Transfer | 1 | 2021 | 790 | 0.110 |
Why?
|
Ultrasonography | 2 | 2020 | 5993 | 0.110 |
Why?
|
Mass Screening | 1 | 2010 | 5446 | 0.110 |
Why?
|
China | 1 | 2020 | 2385 | 0.110 |
Why?
|
Incidence | 3 | 2024 | 21480 | 0.110 |
Why?
|
Aorta | 1 | 2021 | 2028 | 0.110 |
Why?
|
Cardiovascular Diseases | 3 | 2024 | 15652 | 0.110 |
Why?
|
Drug Administration Schedule | 2 | 2019 | 4850 | 0.100 |
Why?
|
Aged, 80 and over | 10 | 2024 | 59489 | 0.100 |
Why?
|
Hospital Mortality | 2 | 2024 | 5343 | 0.100 |
Why?
|
Drug Interactions | 1 | 2017 | 1417 | 0.100 |
Why?
|
Artificial Intelligence | 2 | 2024 | 2659 | 0.100 |
Why?
|
ROC Curve | 1 | 2020 | 3620 | 0.100 |
Why?
|
Echocardiography | 3 | 2020 | 5045 | 0.100 |
Why?
|
Quinolines | 1 | 2018 | 769 | 0.100 |
Why?
|
Lower Extremity | 1 | 2020 | 1226 | 0.100 |
Why?
|
Obesity | 3 | 2023 | 13076 | 0.100 |
Why?
|
Antibodies, Antinuclear | 1 | 2013 | 340 | 0.100 |
Why?
|
Emergency Medicine | 2 | 2019 | 1221 | 0.100 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2013 | 147 | 0.100 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2018 | 5389 | 0.100 |
Why?
|
Cross Infection | 1 | 2021 | 1427 | 0.100 |
Why?
|
Medical Oncology | 2 | 2020 | 2339 | 0.090 |
Why?
|
Point-of-Care Systems | 1 | 2020 | 1217 | 0.090 |
Why?
|
Hypertension, Pulmonary | 1 | 2022 | 1604 | 0.090 |
Why?
|
Neurodegenerative Diseases | 1 | 2020 | 1087 | 0.090 |
Why?
|
History, 21st Century | 1 | 2017 | 1574 | 0.090 |
Why?
|
Thromboplastin | 1 | 2012 | 289 | 0.090 |
Why?
|
Intensive Care Units | 3 | 2021 | 3800 | 0.090 |
Why?
|
Ventricular Dysfunction, Right | 1 | 2016 | 645 | 0.090 |
Why?
|
Hypotension | 1 | 2016 | 885 | 0.090 |
Why?
|
Inpatients | 2 | 2021 | 2564 | 0.090 |
Why?
|
Pandemics | 5 | 2021 | 8703 | 0.090 |
Why?
|
Disease Outbreaks | 1 | 2020 | 1759 | 0.090 |
Why?
|
Enoxaparin | 1 | 2012 | 390 | 0.090 |
Why?
|
Occupational Exposure | 1 | 2020 | 1805 | 0.080 |
Why?
|
Patient Readmission | 1 | 2024 | 3286 | 0.080 |
Why?
|
Swine | 1 | 2020 | 5988 | 0.080 |
Why?
|
Hematologic Neoplasms | 1 | 2021 | 1927 | 0.080 |
Why?
|
Headache | 1 | 2017 | 1259 | 0.080 |
Why?
|
Massachusetts | 2 | 2020 | 8875 | 0.080 |
Why?
|
Factor Xa | 2 | 2020 | 166 | 0.080 |
Why?
|
History, 20th Century | 1 | 2017 | 2761 | 0.080 |
Why?
|
Review Literature as Topic | 2 | 2008 | 297 | 0.080 |
Why?
|
Vena Cava Filters | 3 | 2017 | 272 | 0.080 |
Why?
|
Heart Ventricles | 1 | 2021 | 3832 | 0.080 |
Why?
|
Stress, Psychological | 1 | 2024 | 4533 | 0.080 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 3251 | 0.080 |
Why?
|
Heart Failure | 2 | 2022 | 11840 | 0.070 |
Why?
|
Cohort Studies | 8 | 2024 | 41649 | 0.070 |
Why?
|
Kidney Diseases | 1 | 2018 | 2098 | 0.070 |
Why?
|
Referral and Consultation | 1 | 2020 | 3615 | 0.070 |
Why?
|
Thalidomide | 1 | 2012 | 886 | 0.070 |
Why?
|
Health Personnel | 1 | 2020 | 3390 | 0.070 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2024 | 4628 | 0.070 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2014 | 1608 | 0.070 |
Why?
|
Lung Neoplasms | 3 | 2018 | 13451 | 0.060 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2020 | 3446 | 0.060 |
Why?
|
Quality of Life | 2 | 2024 | 13462 | 0.060 |
Why?
|
Antineoplastic Agents | 2 | 2022 | 13648 | 0.060 |
Why?
|
Cluster Analysis | 1 | 2012 | 2721 | 0.060 |
Why?
|
Shock | 1 | 2008 | 316 | 0.060 |
Why?
|
Diagnosis, Differential | 3 | 2020 | 12976 | 0.060 |
Why?
|
Resource Allocation | 1 | 2008 | 354 | 0.060 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14652 | 0.060 |
Why?
|
Dexamethasone | 1 | 2012 | 1963 | 0.060 |
Why?
|
Longitudinal Studies | 2 | 2019 | 14751 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2023 | 9373 | 0.060 |
Why?
|
Recurrence | 3 | 2023 | 8501 | 0.060 |
Why?
|
Atrial Fibrillation | 1 | 2022 | 5189 | 0.050 |
Why?
|
Evidence-Based Practice | 1 | 2008 | 500 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2022 | 10383 | 0.050 |
Why?
|
Safety | 1 | 2008 | 1157 | 0.050 |
Why?
|
Genotype | 2 | 2021 | 13024 | 0.050 |
Why?
|
Pyridines | 1 | 2014 | 2888 | 0.050 |
Why?
|
Registries | 3 | 2024 | 8297 | 0.050 |
Why?
|
Lung | 1 | 2021 | 10033 | 0.050 |
Why?
|
Sex Characteristics | 2 | 2023 | 2643 | 0.050 |
Why?
|
Germany | 1 | 2024 | 882 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 4 | 2024 | 20659 | 0.050 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2013 | 2159 | 0.050 |
Why?
|
United States | 7 | 2024 | 72903 | 0.050 |
Why?
|
Immunohistochemistry | 1 | 2014 | 11022 | 0.040 |
Why?
|
Chelation Therapy | 1 | 2020 | 77 | 0.040 |
Why?
|
Surge Capacity | 1 | 2020 | 48 | 0.040 |
Why?
|
Stroke | 1 | 2022 | 9747 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39193 | 0.040 |
Why?
|
Cause of Death | 2 | 2021 | 3708 | 0.040 |
Why?
|
Skin Diseases | 1 | 2008 | 1088 | 0.040 |
Why?
|
Censuses | 1 | 2021 | 197 | 0.040 |
Why?
|
Catheterization, Central Venous | 1 | 2005 | 539 | 0.040 |
Why?
|
Algorithms | 1 | 2020 | 14071 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 18071 | 0.040 |
Why?
|
Respiration, Artificial | 2 | 2021 | 2709 | 0.040 |
Why?
|
Organizations, Nonprofit | 1 | 2020 | 105 | 0.040 |
Why?
|
Mitral Valve | 1 | 2008 | 1476 | 0.040 |
Why?
|
Platelet Glycoprotein GPIb-IX Complex | 1 | 2020 | 144 | 0.040 |
Why?
|
Prospective Studies | 4 | 2020 | 54802 | 0.040 |
Why?
|
Azithromycin | 1 | 2020 | 201 | 0.040 |
Why?
|
Sex Factors | 2 | 2024 | 10603 | 0.040 |
Why?
|
Unconsciousness | 1 | 2020 | 250 | 0.040 |
Why?
|
Iodine | 1 | 2021 | 288 | 0.040 |
Why?
|
Pulmonary Circulation | 1 | 2021 | 741 | 0.040 |
Why?
|
Patient Care Management | 1 | 2021 | 303 | 0.040 |
Why?
|
Equipment Failure Analysis | 1 | 2020 | 834 | 0.040 |
Why?
|
Age Factors | 1 | 2014 | 18380 | 0.040 |
Why?
|
Comparative Effectiveness Research | 1 | 2023 | 714 | 0.040 |
Why?
|
Mortality | 2 | 2021 | 2904 | 0.040 |
Why?
|
Blood Coagulation Tests | 1 | 2019 | 263 | 0.040 |
Why?
|
Ferritins | 1 | 2020 | 600 | 0.040 |
Why?
|
Bone Marrow Examination | 1 | 2017 | 155 | 0.040 |
Why?
|
Europe | 1 | 2024 | 3423 | 0.040 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2008 | 1566 | 0.030 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2017 | 185 | 0.030 |
Why?
|
North America | 1 | 2020 | 1285 | 0.030 |
Why?
|
Ethanol | 1 | 2023 | 1323 | 0.030 |
Why?
|
Length of Stay | 2 | 2021 | 6485 | 0.030 |
Why?
|
Group Processes | 1 | 2018 | 224 | 0.030 |
Why?
|
Anemia, Hemolytic | 1 | 2017 | 164 | 0.030 |
Why?
|
Academic Medical Centers | 2 | 2017 | 2780 | 0.030 |
Why?
|
Cerebral Veins | 1 | 2017 | 157 | 0.030 |
Why?
|
Angiography | 1 | 2022 | 1581 | 0.030 |
Why?
|
Hemostatics | 1 | 2019 | 247 | 0.030 |
Why?
|
Hydroxychloroquine | 1 | 2020 | 431 | 0.030 |
Why?
|
Hospital Bed Capacity | 1 | 2017 | 200 | 0.030 |
Why?
|
Prognosis | 3 | 2023 | 29922 | 0.030 |
Why?
|
Embolectomy | 1 | 2016 | 130 | 0.030 |
Why?
|
Severity of Illness Index | 3 | 2021 | 15880 | 0.030 |
Why?
|
Catheterization, Swan-Ganz | 1 | 2016 | 87 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2354 | 0.030 |
Why?
|
Incidental Findings | 1 | 2020 | 697 | 0.030 |
Why?
|
von Willebrand Factor | 1 | 2019 | 676 | 0.030 |
Why?
|
Comorbidity | 2 | 2020 | 10563 | 0.030 |
Why?
|
Intracranial Hemorrhages | 1 | 2020 | 814 | 0.030 |
Why?
|
Radiography, Abdominal | 1 | 2017 | 544 | 0.030 |
Why?
|
Education, Medical, Continuing | 1 | 2020 | 830 | 0.030 |
Why?
|
Medicare | 2 | 2023 | 6823 | 0.030 |
Why?
|
Survivors | 1 | 2024 | 2372 | 0.030 |
Why?
|
Disease Management | 1 | 2005 | 2535 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2022 | 1084 | 0.030 |
Why?
|
Pulmonary Medicine | 1 | 2016 | 222 | 0.030 |
Why?
|
Physician's Role | 1 | 2020 | 927 | 0.030 |
Why?
|
Models, Organizational | 1 | 2016 | 547 | 0.030 |
Why?
|
Deoxycytidine | 1 | 2018 | 889 | 0.030 |
Why?
|
Neural Pathways | 1 | 2024 | 3085 | 0.030 |
Why?
|
Databases, Factual | 2 | 2020 | 8067 | 0.030 |
Why?
|
Survival Analysis | 2 | 2018 | 10070 | 0.030 |
Why?
|
Drug Approval | 1 | 2020 | 818 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2023 | 3513 | 0.030 |
Why?
|
Hematology | 1 | 2016 | 243 | 0.020 |
Why?
|
Postoperative Hemorrhage | 1 | 2016 | 413 | 0.020 |
Why?
|
Splenectomy | 1 | 2013 | 390 | 0.020 |
Why?
|
Spleen | 1 | 2017 | 2296 | 0.020 |
Why?
|
Drug Costs | 1 | 2020 | 1193 | 0.020 |
Why?
|
Hospitals, General | 1 | 2016 | 802 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2020 | 1672 | 0.020 |
Why?
|
Abdominal Pain | 1 | 2017 | 1069 | 0.020 |
Why?
|
Critical Care | 1 | 2024 | 2712 | 0.020 |
Why?
|
Cell-Derived Microparticles | 1 | 2012 | 160 | 0.020 |
Why?
|
Autoantibodies | 1 | 2020 | 2113 | 0.020 |
Why?
|
Health Care Costs | 1 | 2024 | 3242 | 0.020 |
Why?
|
Interdisciplinary Communication | 1 | 2016 | 932 | 0.020 |
Why?
|
Vision Disorders | 1 | 2017 | 1087 | 0.020 |
Why?
|
Pregnancy | 2 | 2023 | 30260 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 1761 | 0.020 |
Why?
|
Thoracic Surgery | 1 | 2016 | 728 | 0.020 |
Why?
|
Medicine | 1 | 2017 | 942 | 0.020 |
Why?
|
Mutation | 3 | 2021 | 30198 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 10729 | 0.020 |
Why?
|
Boston | 1 | 2021 | 9338 | 0.020 |
Why?
|
Animals | 1 | 2020 | 168764 | 0.020 |
Why?
|
Time Factors | 2 | 2020 | 40065 | 0.020 |
Why?
|
Contrast Media | 1 | 2021 | 5329 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2020 | 3050 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2024 | 6547 | 0.020 |
Why?
|
Exercise | 1 | 2024 | 5937 | 0.020 |
Why?
|
Syndrome | 1 | 2013 | 3271 | 0.020 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2011 | 618 | 0.020 |
Why?
|
Survival Rate | 1 | 2021 | 12795 | 0.020 |
Why?
|
Fatigue | 1 | 2013 | 1549 | 0.020 |
Why?
|
Physicians | 1 | 2024 | 4588 | 0.020 |
Why?
|
Genetic Variation | 1 | 2021 | 6610 | 0.020 |
Why?
|
Diagnostic Tests, Routine | 1 | 2011 | 790 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2023 | 22223 | 0.020 |
Why?
|
Cardiology | 1 | 2016 | 1702 | 0.010 |
Why?
|
Child | 2 | 2024 | 80564 | 0.010 |
Why?
|
Odds Ratio | 1 | 2016 | 9649 | 0.010 |
Why?
|
Prevalence | 1 | 2021 | 15842 | 0.010 |
Why?
|
Necrosis | 1 | 2008 | 1617 | 0.010 |
Why?
|
Glucocorticoids | 1 | 2013 | 2132 | 0.010 |
Why?
|
Bone Marrow | 1 | 2013 | 2921 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2016 | 12056 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2018 | 11206 | 0.010 |
Why?
|
Brain | 2 | 2020 | 27171 | 0.010 |
Why?
|
Radiology | 1 | 2016 | 2090 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 2008 | 1394 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2011 | 6499 | 0.010 |
Why?
|
Inflammation | 1 | 2020 | 10850 | 0.010 |
Why?
|
Young Adult | 2 | 2021 | 59889 | 0.010 |
Why?
|
Molecular Targeted Therapy | 1 | 2011 | 2822 | 0.010 |
Why?
|
Quality Assurance, Health Care | 1 | 2008 | 2172 | 0.010 |
Why?
|
Colonic Neoplasms | 1 | 2008 | 2531 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2011 | 8041 | 0.010 |
Why?
|
Societies, Medical | 1 | 2008 | 3956 | 0.010 |
Why?
|
Decision Making | 1 | 2008 | 3965 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 36532 | 0.010 |
Why?
|
Research Design | 1 | 2008 | 6209 | 0.010 |
Why?
|